India, April 1 -- Candel Therapeutics, Inc. (CADL), Tuesday, announced the publication of Phase 1b clinical trial results for CAN-2409 in newly diagnosed high-grade glioma in the journal Neuro-Oncology.
The phase 1b clinical trial evaluated the safety and tolerability of the combination of CAN-2409 and Nivolumab plus standard of care in newly diagnosed high-grade glioma patients.
The study demonstrated encouraging survival benefits and immune activation. The trial enrolled 41 patients, with a subset showing notable improvements.
Patients with MGMT-methylated tumors who underwent total tumor resection had a median overall survival of 30.6 months. CAN-2409 treatment induced systemic immune activation, enhancing T-cell diversity and reducin...